Literature DB >> 28366351

When to Pick the Nose: Out-of-Hospital and Emergency Department Intranasal Administration of Medications.

Megan A Rech1, Brian Barbas2, Whitney Chaney3, Elizabeth Greenhalgh3, Charles Turck4.   

Abstract

The intranasal route for medication administration is increasingly popular in the emergency department and out-of-hospital setting because such administration is simple and fast, and can be used for patients without intravenous access and in situations in which obtaining an intravenous line is difficult or time intensive (eg, for patients who are seizing or combative). Several small studies (mostly pediatric) have shown midazolam to be effective for procedural sedation, anxiolysis, and seizures. Intranasal fentanyl demonstrates both safety and efficacy for the management of acute pain. The intranasal route appears to be an effective alternative for naloxone in opioid overdose. The literature is less clear on roles for intranasal ketamine and dexmedetomidine.
Copyright © 2017 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28366351     DOI: 10.1016/j.annemergmed.2017.02.015

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  12 in total

1.  Authors' Reply to M.S. Raghuraman: "Intranasal Dexmedetomidine for Procedural Sedation in Children, a Suitable Alternative to Chloral Hydrate".

Authors:  Giorgio Cozzi; Stefania Norbedo; Egidio Barbi
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

Review 2.  Managing pain and distress in children undergoing brief diagnostic and therapeutic procedures.

Authors:  Evelyne D Trottier; Marie-Joëlle Doré-Bergeron; Laurel Chauvin-Kimoff; Krista Baerg; Samina Ali
Journal:  Paediatr Child Health       Date:  2019-12-09       Impact factor: 2.253

3.  [Transdermal intoxication through broken opioid ampules : Accidental intoxication in a paramedic].

Authors:  U Bartram; R Schmidt
Journal:  Anaesthesist       Date:  2020-01-30       Impact factor: 1.041

Review 4.  Intranasal Therapy to Stop Status Epilepticus in Prehospital Settings.

Authors:  John Benfield; Alberto Musto
Journal:  Drugs R D       Date:  2018-03

Review 5.  Essential pharmacologic options for acute pain management in the emergency setting.

Authors:  David H Cisewski; Sergey M Motov
Journal:  Turk J Emerg Med       Date:  2018-12-10

6.  Intranasal sufentanil versus intravenous morphine for acute severe trauma pain: A double-blind randomized non-inferiority study.

Authors:  Marc Blancher; Maxime Maignan; Cyrielle Clapé; Jean-Louis Quesada; Roselyne Collomb-Muret; François Albasini; François-Xavier Ageron; Stephanie Fey; Audrey Wuyts; Jean-Jacques Banihachemi; Barthelemy Bertrand; Audrey Lehmann; Claire Bollart; Guillaume Debaty; Raphaël Briot; Damien Viglino
Journal:  PLoS Med       Date:  2019-07-16       Impact factor: 11.069

7.  Pharmacokinetics and pharmacodynamics of intranasal remimazolam-a randomized controlled clinical trial.

Authors:  Marija Pesic; Frank Schippers; Rob Saunders; Lyn Webster; Martin Donsbach; Thomas Stoehr
Journal:  Eur J Clin Pharmacol       Date:  2020-09-04       Impact factor: 2.953

Review 8.  Benzodiazepines: Their Use either as Essential Medicines or as Toxics Substances.

Authors:  Edilma Sanabria; Ronald Edgardo Cuenca; Miguel Ángel Esteso; Mauricio Maldonado
Journal:  Toxics       Date:  2021-02-01

9.  Post-Discharge Effects and Parents' Opinions of Intranasal Fentanyl with Oral Midazolam Sedation in Pediatric Dental Patients: A Cross-Sectional Study.

Authors:  Roaa I Alhaidari; Maha A AlSarheed
Journal:  Children (Basel)       Date:  2022-01-22

10.  Evaluation of a clinical protocol using intranasal fentanyl for treatment of vaso-occlusive crisis in sickle cell patients in the emergency department.

Authors:  Hugo Paquin; Evelyne D Trottier; Yves Pastore; Nancy Robitaille; Marie-Joelle Dore Bergeron; Benoit Bailey
Journal:  Paediatr Child Health       Date:  2019-03-07       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.